We have previously demonstrated that sensitization to allergens, with a TLR4 or TLR9 agonist, prevents the development of Th2 lung inflammation without shifting the lung inflammation towards a Th1/Th17 pattern [1,2,3]. The gene discussed is TLR9; the disease is inflammation.